Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Polymeric Multivalent Fc Binding Peptides‐Fabricated Clinical Compounding Bispecific Antibody Potentiates Dual Immunotherapy Targeting PD1 and CTLA‐4 ; day:28 ; month:11 ; year:2024 ; extent:13
Advanced science ; (28.11.2024) (gesamt 13)
- Creator
-
Liu, Zongyu
Chu, Hongyu
Zhao, Weidong
Yang, Chenguang
Liu, Tongjun
Shen, Na
Tang, Zhaohui
- DOI
-
10.1002/advs.202408899
- URN
-
urn:nbn:de:101:1-2411281347419.639960494018
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Liu, Zongyu
- Chu, Hongyu
- Zhao, Weidong
- Yang, Chenguang
- Liu, Tongjun
- Shen, Na
- Tang, Zhaohui
Other Objects (12)
Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Compounding wines
Understanding compounding
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
Pharmaceutical compounding and dispensing
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs
Bispecific antibodies
Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Compounding wines
Understanding compounding
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
Pharmaceutical compounding and dispensing
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs
Bispecific antibodies
Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Compounding wines
Understanding compounding
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming
Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy
Pharmaceutical compounding and dispensing
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs